TG Therapeutics Inc (TGTX)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- Session momentumUp 5.3% on the session+9
- 12-month trend+68% over the past year+6
- 52-week positionIn the upper quarter of its 52-week range+18
- QualityRevenue growing 76% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is **analyst/event-driven** rather than fundamental, since the insider sale and conference participation headlines are routine and don't reflect a change in earnings, product, or M&A outlook. Continuation likelihood over the next few weeks is **low-to-moderate**, as these headlines typically have limited lasting price impact absent a substantive catalyst. Informational only — not financial advice.
- Insider Decision: Laurence N Charney Offloads $274K Worth Of TG Therapeutics StockBenzinga · 2026-09-15
- TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceYahoo · 2026-09-10
- HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $78 Price TargetBenzinga · 2026-09-01
- Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should KnowSeekingAlpha · 2026-08-31
- TG Therapeutics (NASDAQ:TGTX): A Fitting Candidate for Affordable GrowthChartMill · 2026-08-31
Any AI summary is an interpretation of public news, not advice or a price target.